Through transcriptomic analyses, we propose that PELI2 primarily restrains CRC progression via suppression of the MAPK signaling pathway and its downstream EMT program, with potential contributions to cell cycle regulation, such as Cyclin D1 modulation. Here, PELI2 is linked to colorectal carcinoma.